Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.85 +0.20 (+0.80%)

Streaming Delayed Price Updated: 3:30 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

What's going on in today's session: S&P500 most active stocks ↗

Today 14:05 EST

Via Chartmill

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

Today 10:27 EST

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗

Today 10:19 EST

Via Stocktwits

Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock ↗

Today 10:00 EST

Via Benzinga

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗

January 21, 2026

Via Stocktwits

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

Today 9:41 EST

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

The Best Stocks to Invest $40 in to Start the New Year Off Right ↗

January 24, 2026

Both could reward patient investors down the line.

Via The Motley Fool

Topics Intellectual Property World Trade

AGG vs. VCIT: The Same Tiny Fee, Completely Different Holdings ↗

January 24, 2026

Explore how portfolio breadth and risk profiles set these two leading bond ETFs apart for income-focused investors.

Via The Motley Fool

Topics Bonds ETFs

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research ↗

January 23, 2026

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

Via Benzinga

The HSR Paradox: How 'Early Termination' is Reshaping the 2026 M&A Landscape

January 23, 2026

A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade...

Via MarketMinute

Topics Earnings Economy

The Top Stock to Buy With $30 for 2026 ↗

January 23, 2026

It's a great opportunity to "buy low."

Via The Motley Fool

Topics Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Via MarketMinute

Topics Economy

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗

January 22, 2026

Via Chartmill

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

How Is The Market Feeling About Pfizer Inc? ↗

January 22, 2026

Via Benzinga

Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap? ↗

January 22, 2026

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Via The Motley Fool

Topics Intellectual Property

Is This Dividend King Stock a Buy After a Major Development? ↗

January 21, 2026

After a strong performance in 2025, Johnson & Johnson is starting the new year right.

Via The Motley Fool

Topics Government World Trade

Why Are Novavax (NVAX) Shares Soaring Today

January 21, 2026

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant...

Via StockStory

Topics Artificial Intelligence Supply Chain

Beyond the Silicon: NVIDIA and Eli Lilly Launch $1 Billion ‘Physical AI’ Lab to Rewrite the Rules of Medicine

January 21, 2026

In a move that signals the arrival of the "Bio-Computing" era, NVIDIA (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have officially launched a landmark $1 billion AI co-innovation lab. Announced during the...

Via TokenRing AI

Topics Artificial Intelligence Economy Intellectual Property

J&J Forecasts $100 Billion Milestone for 2026 as Trump Drug Pricing Deals Reshape the Pharma Landscape

January 21, 2026

NEW BRUNSWICK, N.J. — In a landmark display of resilience and strategic pivoting, Johnson & Johnson (NYSE: JNJ) reported fourth-quarter 2025 revenues of $24.56 billion on Wednesday, January 21, 2026,...

Via MarketMinute

Topics Earnings Economy Government

3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer ↗

January 21, 2026

One of these suggested stocks features a dividend yield topping 10%.

Via The Motley Fool

Topics Intellectual Property

Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment

January 20, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

The 50.9 Mirage: Is the Manufacturing Expansion a True Recovery or a Tariff-Induced Sugar High?

January 20, 2026

The American manufacturing sector has finally crossed the threshold into expansion territory, with the latest Institute for Supply Management (ISM) Manufacturing PMI rising to 50.9. This mark...

Via MarketMinute

Topics Economy Supply Chain World Trade

These S&P500 stocks are the most active in today's session ↗

January 20, 2026

Via Chartmill

Novavax Shares Rise After Licensing Deal With Pfizer ↗

January 20, 2026

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant.

Via Benzinga

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗

January 20, 2026

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.